Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing

References

1. 1.↵
   International Organization for Standardization, Q5A: Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin. 1999; pp 1–27.

   Google Scholar
2. 2.↵
   World Health Organization. Good Manufacturing Practices for Biological Products. 2016.

   Google Scholar
3. 3.↵
   U.S. Food and Drug Administration, Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients: Guidance for Industry, 2016.

   Google Scholar
4. 4.↵
   Pharmaceutical Inspection Convention/Cooperation Scheme (PIC/S), Inspection of Biotechnology Manufactures. (PIC/S), Aide Memoire, 2006.

   Google Scholar
5. 5.↵
   World Health Organization. Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products, 2004.

   Google Scholar
6. 6.↵
   World Health Organization. Requirements for the Collection, Processing and Control of Blood, Blood Components and Plasma Derivatives, 1994.

   Google Scholar
7. 7.↵
   U.S. Food and Drug Administration, SOPP 8401.4: Review Responsibilities for the CMC Section of Biologic License Applications and Supplements, 2005.

   Google Scholar
8. 8.↵
   U.S. Food and Drug Administration, Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use, 1996.

   Google Scholar
9. 9.↵
   1. Palberg T.,
   2. Johnson J.,
   3. Probst S.,
   4. Gil P.,
   5. Rogalewicz J.,
   6. Kennedy M.,
   7. Green K.,
   8. Chalk S.

   Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances. BioPharm Int. 2011, 24 (8), 44–60.

   OpenUrlGoogle Scholar
10. 10.↵
    1. Odum J.

    Focusing on the Future of Biologics Manufacturing. Presented at ISPE 2013 Supplier Showcase Presentations, New Jersey, 12 September 2013.

    Google Scholar
11. 11.↵
    International Society for Pharmaceutical Engineering, Baseline Guide Volume 6: Biopharmaceutical Manufacturing Facilities, 2013.

    Google Scholar
12. 12.↵
    1. Brown F.,
    2. Lubiniecki A.

    1. Ogrady J.,
    2. Losikoff A.,
    3. Poiley J.,
    4. Fickett D.,
    5. Oliver C.

    Virus Removal Studies Using Nanofiltration Membranes. In Viral Safety and Evaluation of Viral Clearance from Biopharmaceutical Products; Brown F., Lubiniecki A., Eds.; 1996; 319–326.

    Google Scholar
13. 13.↵
    1. Burnouf-Radosevich M.,
    2. Appourchaux P.,
    3. Huart J. J.,
    4. Burnouf T.

    Nanofiltration, A New Specific Virus Elimination Method Applied to High-Purity Factor-IX and Factor-XI Concentrates. Vox Sang. 1994, 67 (2), 132–138.

    OpenUrlPubMedGoogle Scholar
14. 14.↵
    1. Dichtelmuller H. O.,
    2. Biesert L.,
    3. Fabbrizzi F.,
    4. Gajardo R.,
    5. Groner A.,
    6. von Hoegen I.,
    7. Jorguera J. I.,
    8. Kempf C.,
    9. Kreil T. R.,
    10. Pifat D.,
    11. Osheroff W.,
    12. Poelsler G.

    Robustness of Solvent/Detergent Treatment of Plasma Derivatives: A Data Collection from Plasma Protein Therapeutics Association Member Companies. Transfusion, 2009, 49 (9), 1931–1943.

    OpenUrlCrossRefGoogle Scholar
15. 15.↵
    1. Robertson J. S.

    1. Dichtelmuller H.

    Robustness Studies on Virus Inactivation: Definition of Parameters and Their Generic Use. In PDA/EMEA European Virus Safety Forum; Robertson J. S., Ed.; 2004; 125–127.

    Google Scholar
16. 16.↵
    1. Kelley B. D.,
    2. Jakubik J.,
    3. Vicik S.

    Viral Clearance Studies on New and Used Chromatography Resins: Critical Review of a Large Dataset. Biologicals, 2008, 36 (2), 88–98.

    OpenUrlPubMedGoogle Scholar
17. 17.↵
    1. Shukla A. A.,
    2. Hubbard B.,
    3. Tressel T.,
    4. Guhan S.,
    5. Low D.

    Downstream Processing of Monoclonal Antibodies—Application of Platform Approaches. J. Chromatogr. B-Analyt. Technol. Biomed. Life Sci. 2007, 848 (1), 28–39.

    OpenUrlGoogle Scholar
18. 18.↵
    1. Brorson K.,
    2. Krejci S.,
    3. Lee K.,
    4. Hamilton E.,
    5. Stein K.,
    6. Xu Y.

    Bracketed Generic Inactivation of Rodent Retroviruses by Low pH Treatment for Monoclonal Antibodies and Recombinant Proteins. Biotechnol. Bioeng. 2003, 82 (3), 321–329.

    OpenUrlCrossRefPubMedGoogle Scholar
19. 19.↵
    European Medicines Agency. Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses, 1996.

    Google Scholar
20. 20.↵
    1. Odum J.,
    2. Witcher M.

    Technology's Impact on the Biomanufacturing Facility of the Future. In Encyclopedia of Industrial Biotechnology; John Wiley & Sons, Inc., 2016, DOI: 10.1002/9780470054581.eib663.

    OpenUrlCrossRefGoogle Scholar